DENODO
Denodo, a leader in data management is opening their new Middle East regional head office in Riyadh, Kingdom of Saudi Arabia (KSA) today. To inaugurate the office opening, Denodo is launching their first “Denodo Data Day” with Her Highness Dr. Shaikha Dheya Bint Ebrahim Al Khalifa and delegates from Google Cloud, among others, as guest speakers. The new office will support new and existing Denodo customers and partners in the Middle East, providing them with direct access to the company’s experts in logical data management and AI-supported data solutions. This regional expansion is a testament to Denodo’s growing business and its customers in the region.
"We are thrilled to expand our presence in the Middle East with the opening of our new office in Riyadh, a city known for its rapid growth and innovation," said Ángel Viña, CEO and founder at Denodo. "Riyadh is host to a growing number of companies and government agencies, particularly in the technology, finance, and energy sectors – including the ambitious NEOM City. This new office will enable us to better serve our customers in the Middle East, providing them with our 'fearless data' approach to logical data management and the cutting-edge solutions they need to stay ahead in today's competitive market."
Denodo has made significant investments in AI and GenAI, which supports the Kingdom’s Vision 2030’s AI goals of making Saudi Arabia an international AI hub. Saudi Arabia is investing heavily in AI to diversify its economy. PwC recently published estimates that AI will contribute more than $135 billion to Saudi Arabia’s economy by 2030, which would lessen its reliance on revenue from oil. The Kingdom’s National Strategy aims for a global AI ranking of 15 by 2030. Recently, Saudi Arabia gained the top spot for AI government strategy. However, data management remains a hurdle. Traditional methods are complex and slow, hindering businesses seeking AI's potential in areas like customer experience.
“Saudi Arabia is the largest economy in the Middle East, and it’s going through an amazing period of growth and change,” said Gabriele Obino, regional vice president and general manager, Middle East, Denodo. “Denodo is a pioneer in logical data management, and we are offering local and regional organizations, in various industries including aviation, healthcare and Government, the opportunity to start or continue their digital transformations to modern cloud and GenAI-based data solutions.”
By fostering strong collaboration with key technology providers and systems integrators, such as the global cloud hyperscaler Google Cloud, Denodo demonstrates that its customers in the Middle East have access to the most innovative and comprehensive data solutions available, empowering them to make informed, data-driven decisions to help them stay ahead in today's competitive landscape.
Niall McDonagh, director, EMEA Public Sector, Google Cloud, emphasized the unique position of Google Cloud in Saudi Arabia: “As the only cloud provider with a dedicated region in Saudi Arabia, Google Cloud is uniquely positioned to support the digital transformation needs of this vibrant market. Our partnership with Denodo for the inaugural Denodo Data Day in Riyadh is a pivotal moment for us to showcase how our cloud solutions, coupled with Denodo’s logical data management technology, can drive significant advancements in key industries such as finance, healthcare, government, and education. We are also excited to highlight the capabilities of our Google Cloud Center of Excellence, which provides strategic guidance and cloud technology expertise.”
About Denodo
Denodo is a leader in data management. The award-winning Denodo Platform is the leading logical data management platform for delivering data in the language of business, at the speed of business, for all data-related initiatives across the organization. Realizing more than 400% ROI and millions of dollars in benefits, Denodo’s customers across enterprises in 30+ industries all over the world have received payback in less than six months. For more information, visit denodo.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240602513059/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kolmar Korea Named One of the TIME’s World’s Best Companies for Sustainable Growth26.12.2024 15:00:00 CET | Press release
Ranks 125th Among 500 Companies Around the GlobeTop 10% in the Environmental Sector Among 3,000 Major Global Companies Kolmar Korea (KRX: 024720) has been recognized by TIME Magazine as one of the World’s Best Companies for Sustainable Growth 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241226863828/en/ Kolmar Korea on TIME's World's Best Companies in Sustainable Growth 2025 (Image: Kolmar Korea) On November 27, TIME, in collaboration with a global market research firm Statista, unveiled a list of the top 500 companies worldwide, demonstrating exceptional sustainable growth. Kolmar Korea took place 125th around the globe and 6th among Korean companies. Notably, it was the only Korean cosmetics company on the list, which featured a total of 23 Korean companies. The rankings were based on an evaluation of revenue growth, financial stability, and environmental impact, each contributing equally to a final score out of 10
Seoul Semiconductor: Philips Lighting Products Ordered to Recall 7-Year-Old Items26.12.2024 08:00:00 CET | Press release
The German District Court of Düsseldorf, on November 19 ruled in favor of Seoul Semiconductor (KOSDAQ:046890) in the patent infringement lawsuits, and also ordered that products manufactured by Philips Lighting and sold since March 2017 be recalled and destroyed. The Court also ruled that a fine of up to €250,000 would be imposed for each violation of this order. On December 17, the German Federal Patent Court also affirmed the validity of these patents, which solidifies the strength of many related patents. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241225151382/en/ Application Examples with CRI 70 or Higher (Photo: Seoul Semiconductor) These court orders relate to the core technology used to achieve CRI 70 (Color Rendering Index 70%) or higher, applicable to all home lighting, automotive lighting products, IT flash, and backlights. Since the effects of these judgments are applicable to all products infringing on the pa
ispace-EUROPE and the Italian Space Agency (ASI) Sign Payload Services Agreement to Transport a Laser Retroreflector Array (LaRA2) on the Moon Surface26.12.2024 08:00:00 CET | Press release
Agreement Marks Significant Step Towards Increasing Italy’s Contribution to advancing Lunar Exploration ispace EUROPE S.A. (ispace-EUROPE), the Luxembourg-based subsidiary of ispace, inc., and the Italian Space Agency (ASI) have signed a payload services agreement to transport a Laser Retroreflector Array (LaRA2) to enable accurate position measurements on the Moon via laser ranging experiments, the two organizations announced today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241225137548/en/ The shape of LaRA2, a palm-sized dome (Photo: Business Wire) The agreement marks the first full-scale contract between ispace-EUROPE and ASI, with both organizations looking to joint future lunar development. LaRA2 is a small, robust, and lightweight instrument built to work without any power source and to survive the harsh surface conditions on the Moon for an extended period of time. It features a precise array of retroreflectors
Datopotamab Deruxtecan Application in the EU for Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer Voluntarily Withdrawn24.12.2024 08:00:00 CET | Press release
Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: AZN) have voluntarily withdrawn the marketing authorization application (MAA) in the EU for datopotamab deruxtecan (Dato-DXd) for the treatment of adult patients with locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) based on the TROPION-Lung01 phase 3 trial. The decision to withdraw the MAA was informed by feedback from the Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA). Daiichi Sankyo and AstraZeneca will continue to work to bring datopotamab deruxtecan to patients with lung cancer in the EU who can benefit and are committed to unlocking the potential of this medicine in lung cancer through our robust clinical development program which includes seven pivotal trials in various lung cancer settings. Datopotamab deruxtecan is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed by Dai
Vertex to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 1323.12.2024 22:05:00 CET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Dr. Reshma Kewalramani, Chief Executive Officer and President, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 10:30 a.m. ET/7:30 a.m. PT. A live webcast of management's remarks will be available through the Vertex website, www.vrtx.com in the "Investors" section under the "News and Events" page. A replay of the conference webcast will be archived on the company's website. About Vertex Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has approved medicines that treat the underlying causes of multiple chronic, life-shortening genetic diseases — cystic fibrosis, sickle cell disease and transfusion-dependent beta thalassemia — and continues to advance clinical and research programs in these diseases. Vertex also has a robust clinical pipeline of investigational
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom